JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

NVS

148.01

-1.18%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

NVS

148.01

-1.18%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

NVS

148.01

-1.18%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

NVS

148.01

-1.18%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

NVS

148.01

-1.18%↓

Strona główna・Stock List・Eli Lilly and Co.

Eli Lilly and Co.

Closed

SectorHealthcare

1,004 -0.33

Buy Sell

Overview

Share price change

24h

Current

Min

997

Max

1005.94

Key metrics
By Trading Economics
Income	758M 7.4B
Sales	507M 20B
P/E Sector Avg	34.327 51.415
EPS	8.55
Dividend yield	0.66
Profit margin	37.355
Employees	50,000
EBITDA	971M 9.4B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+25.67% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	0.66% 2.34%
Next Earnings	5 sie 2026
Next Dividend date	10 cze 2026
Next Ex Dividend date	14 sie 2026

Market Stats
By TradingEconomics
Market Cap	87B 862B
Previous open	1004.33
Previous close	1004

News Sentiment

By Acuity

25%

75%

39 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 884.54 Support & Resistance

Eli Lilly and Co. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 kwi 2026, 12:01 UTC

Earnings

Major Market Movers

Eli Lilly Shares Jump On Guidance Boost, Earnings Above Expectations

7 maj 2026, 09:30 UTC

Earnings

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 maj 2026, 12:36 UTC

Earnings

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 maj 2026, 10:12 UTC

Earnings

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 maj 2026, 09:58 UTC

Earnings

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

30 kwi 2026, 20:59 UTC

Hot Stocks

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

30 kwi 2026, 20:12 UTC

Earnings

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 kwi 2026, 16:43 UTC

Earnings

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

30 kwi 2026, 16:10 UTC

Market Talk

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

30 kwi 2026, 15:13 UTC

Earnings

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 kwi 2026, 14:58 UTC

Earnings

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

30 kwi 2026, 14:53 UTC

Earnings

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

30 kwi 2026, 14:50 UTC

Earnings

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

30 kwi 2026, 14:42 UTC

Earnings

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

30 kwi 2026, 14:39 UTC

Earnings

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

30 kwi 2026, 14:35 UTC

Earnings

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

30 kwi 2026, 14:24 UTC

Earnings

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

30 kwi 2026, 14:17 UTC

Earnings

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

30 kwi 2026, 13:56 UTC

Earnings

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 kwi 2026, 13:37 UTC

Hot Stocks

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 kwi 2026, 12:32 UTC

Market Talk

Earnings

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

30 kwi 2026, 12:29 UTC

Market Talk

Earnings

Eli Lilly CEO Says Foundayo Adoption Could Take Time -- Market Talk

30 kwi 2026, 12:23 UTC

Market Talk

Earnings

Eli Lilly CEO Says International Demand for GLP-1s Is Ramping Up -- Market Talk

30 kwi 2026, 12:10 UTC

Earnings

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 kwi 2026, 12:08 UTC

Earnings

Eli Lilly Sales, Profits Surge on Weight-Loss Drugs -- WSJ

30 kwi 2026, 12:04 UTC

Market Talk

Earnings

Eli Lilly's GLP-1 Party Has No End in Sight -- Market Talk

30 kwi 2026, 11:39 UTC

Hot Stocks

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 kwi 2026, 11:08 UTC

Earnings

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 kwi 2026, 10:50 UTC

Earnings

Eli Lilly Raises 2026 Performance Margin View to 47%-48.5% From 46%-47.5% >LLY

30 kwi 2026, 10:49 UTC

Earnings

Eli Lilly Had Seen 2026 Revenue $80B-$83B, Adjusted EPS $33.50-$35.00 >LLY

Peer Comparison

Price change

Eli Lilly and Co. Forecast

Price Target

By TipRanks

25.67% upside

12 Months Forecast

Average 1,262.85 USD 25.67%

High 1,500 USD

Low 850 USD

Based on 22 Wall Street analysts offering 12 month price targets forEli Lilly and Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

22 ratings

Buy

Hold

Sell

Based on 22 analysts giving stock ratings to Eli Lilly and Co. - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 884.54Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

39 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.